Serum and Synovial Levels of Cathepsin G and Cathepsin K in Patients with Psoriatic Arthritis and Their Correlation with Disease Activity Indices

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Oct 28

PMID 37892071

Authors

Stanislava Dimitrova Popova-Belova

Mariela Gencheva Geneva-Popova

Krasimir Iliev Kraev

Velichka Zaharieva Popova

Affiliations

Soon will be listed here.

Abstract

This retrospective case-control study examined the relationship between the serum and synovial levels of cathepsin G (CatG) and cathepsin K (CatK) in patients with psoriatic arthritis (PsA) and their association with disease activity. Methods: This case-control study involved 156 PsA patients, 50 patients with gonarthrosis (GoA), and 30 healthy controls. The target parameters were measured using enzyme-linked immunosorbent assay (ELISA) kits. The serum levels of CatG and CatK were found to be significantly higher in PsA patients compared to both control groups ( < 0.001). Moreover, they could distinguish PsA patients from healthy controls with 100% accuracy. Synovial fluid CatG and CatK were positively associated with the following indicators of disease activity: the VAS (rs = 0.362, rs = 0.391); the DAPSA (rs = 0.191, rs = 0.182); and the mCPDAI (rs = 0.378, rs = 0.313). Our results suggest that serum and synovial fluid CatG and CatK levels could serve as biomarkers for PsA. In PsA patients with synovial fluid crystals, elevated synovial CatG levels demonstrated a sensitivity of 89.54% and a specificity of 86.00% in distinguishing them from PsA patients without crystals. Similarly, elevated synovial CatK levels had a sensitivity of 93.67% and a specificity of 94.34% for distinguishing PsA patients with synovial fluid crystals from those without. Furthermore, the synovial fluid levels of both CatG and CatK showed positive associations with key indicators of disease activity, including the visual analog scale (VAS) (rs = 0.362, rs = 0.391), the disease activity in psoriatic arthritis (DAPSA) (rs = 0.191, rs = 0.182), and the modified composite psoriatic disease activity index (mCPDAI) (rs = 0.378, rs = 0.313). In conclusion, our findings suggest that the serum and synovial fluid levels of CatG and CatK hold promise as potential biomarkers for assessing disease activity in psoriatic arthritis.

References

Hansen T, Petrow P, Gaumann A, Keyszer G, Otto M, Kirkpatrick C . Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath. Mod Pathol. 2001; 14(4):318-24. DOI: 10.1038/modpathol.3880309. View

Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates L, Veale J D . Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2010; 70(2):272-7. DOI: 10.1136/ard.2010.129379. View

Rupanagudi K, Kulkarni O, Lichtnekert J, Darisipudi M, Mulay S, Schott B . Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2013; 74(2):452-63. DOI: 10.1136/annrheumdis-2013-203717. View

Biasizzo M, Javorsek U, Vidak E, Zaric M, Turk B . Cysteine cathepsins: A long and winding road towards clinics. Mol Aspects Med. 2022; 88:101150. DOI: 10.1016/j.mam.2022.101150. View

Delgado M, Clark-Lewis I, Loetscher P, Langen H, Thelen M, Baggiolini M . Rapid inactivation of stromal cell-derived factor-1 by cathepsin G associated with lymphocytes. Eur J Immunol. 2001; 31(3):699-707. DOI: 10.1002/1521-4141(200103)31:3<699::aid-immu699>3.0.co;2-6. View

Feng H, Xing W, Han Y, Sun J, Kong M, Gao B . Tendon-derived cathepsin K-expressing progenitor cells activate Hedgehog signaling to drive heterotopic ossification. J Clin Invest. 2020; 130(12):6354-6365. PMC: 7685727. DOI: 10.1172/JCI132518. View

Maison C, Villiers C, Colomb M . Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G. J Immunol. 1991; 147(3):921-6. View

Huang S, Thomsson K, Jin C, Alweddi S, Struglics A, Rolfson O . Cathepsin g Degrades Both Glycosylated and Unglycosylated Regions of Lubricin, a Synovial Mucin. Sci Rep. 2020; 10(1):4215. PMC: 7060204. DOI: 10.1038/s41598-020-61161-5. View

Zhao Q, Jia Y, Xiao Y . Cathepsin K: a therapeutic target for bone diseases. Biochem Biophys Res Commun. 2009; 380(4):721-3. DOI: 10.1016/j.bbrc.2009.01.139. View

10.

Hirai T, Kanda T, Sato K, Takaishi M, Nakajima K, Yamamoto M . Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation. J Immunol. 2013; 190(9):4805-11. DOI: 10.4049/jimmunol.1200901. View

11.

Veale D, Fearon U . The pathogenesis of psoriatic arthritis. Lancet. 2018; 391(10136):2273-2284. DOI: 10.1016/S0140-6736(18)30830-4. View

12.

Barrett A . Cathepsin G. Methods Enzymol. 1981; 80 Pt C:561-5. DOI: 10.1016/s0076-6879(81)80044-4. View

13.

Lecaille F, Bromme D, Lalmanach G . Biochemical properties and regulation of cathepsin K activity. Biochimie. 2007; 90(2):208-26. DOI: 10.1016/j.biochi.2007.08.011. View

14.

Cohen-Mazor M, Mazor R, Kristal B, Sela S . Elastase and cathepsin G from primed leukocytes cleave vascular endothelial cadherin in hemodialysis patients. Biomed Res Int. 2014; 2014:459640. PMC: 4024418. DOI: 10.1155/2014/459640. View

15.

Velvart M, Fehr K . Degradation in vivo of articular cartilage in rheumatoid arthritis and juvenile chronic arthritis by cathepsin G and elastase from polymorphonuclear leukocytes. Rheumatol Int. 1987; 7(5):195-202. DOI: 10.1007/BF00541377. View

16.

Zhang Q, Zhou D, Wang H, Tan J . Heterotopic ossification of tendon and ligament. J Cell Mol Med. 2020; 24(10):5428-5437. PMC: 7214162. DOI: 10.1111/jcmm.15240. View

17.

Pham C . Neutrophil serine proteases fine-tune the inflammatory response. Int J Biochem Cell Biol. 2008; 40(6-7):1317-33. PMC: 2440796. DOI: 10.1016/j.biocel.2007.11.008. View

18.

Delgado D, Lambert B, Boutris N, McCulloch P, Robbins A, Moreno M . Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018; 2(3):e088. PMC: 6132313. DOI: 10.5435/JAAOSGlobal-D-17-00088. View

19.

Cheng X, Narisawa M, Wang H, Piao L . Overview of multifunctional cysteinyl cathepsins in atherosclerosis-based cardiovascular disease: from insights into molecular functions to clinical implications. Cell Biosci. 2023; 13(1):91. PMC: 10197855. DOI: 10.1186/s13578-023-01040-4. View

20.

Perez-Chada L, Merola J . Comorbidities associated with psoriatic arthritis: Review and update. Clin Immunol. 2020; 214:108397. DOI: 10.1016/j.clim.2020.108397. View